Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:RAPPNASDAQ:UPXINASDAQ:VIRINASDAQ:ZYBT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeRAPPRapport Therapeutics$10.23+8.8%$10.04$6.43▼$29.74$373.38MN/A176,895 shs125,768 shsUPXIUpexi$10.91-4.1%$7.80$1.90▼$22.57$413.65M-0.27861,883 shs59,288 shsVIRIVirios Therapeutics$5.18-2.1%$4.82$0.13▼$1.04$99.76M1.581.05 million shs35,069 shsZYBTZhengye Biotechnology$7.99-12.8%$8.05$3.50▼$14.30$376.86MN/A372,661 shs392,223 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceRAPPRapport Therapeutics+11.90%-13.12%-17.03%-5.91%+939,999,900.00%UPXIUpexi+14.14%+6.55%-19.12%+358.87%+2.43%VIRIVirios Therapeutics0.00%-1.15%+3.19%+20.75%+2,307.06%ZYBTZhengye Biotechnology-1.29%+7.39%-32.05%+113.52%+915,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationRAPPRapport Therapeutics1.844 of 5 stars3.51.00.00.01.91.70.6UPXIUpexi1.6454 of 5 stars0.05.00.00.02.53.30.0VIRIVirios Therapeutics0.1635 of 5 stars1.30.00.00.00.00.80.6ZYBTZhengye BiotechnologyN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceRAPPRapport Therapeutics 3.00Buy$32.67219.32% UpsideUPXIUpexi 0.00N/AN/AN/AVIRIVirios Therapeutics 2.50Moderate Buy$3.00-42.08% DownsideZYBTZhengye Biotechnology 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VIRI, ZYBT, UPXI, and RAPP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/8/2025RAPPRapport TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Outperform$28.004/8/2025RAPPRapport TherapeuticsCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMkt Outperform(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookRAPPRapport TherapeuticsN/AN/AN/AN/AN/AN/AUPXIUpexi$16.56M24.98N/AN/A$2.85 per share3.83VIRIVirios TherapeuticsN/AN/AN/AN/A$0.20 per shareN/AZYBTZhengye Biotechnology$189.75M1.99N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateRAPPRapport Therapeutics-$34.79M-$3.45N/AN/AN/AN/AN/AN/A8/14/2025 (Estimated)UPXIUpexi-$23.66MN/A0.00∞N/AN/AN/AN/A7/8/2025 (Estimated)VIRIVirios Therapeutics-$5.30M-$0.27N/AN/AN/AN/A-130.33%-115.00%8/6/2025 (Estimated)ZYBTZhengye BiotechnologyN/AN/A0.00∞N/AN/AN/AN/AN/ALatest VIRI, ZYBT, UPXI, and RAPP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/16/2025Q1 2025UPXIUpexiN/A-$2.87N/A-$2.87N/A$3.16 million5/8/2025Q1 2025RAPPRapport Therapeutics-$0.77-$0.68+$0.09-$0.68N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthRAPPRapport TherapeuticsN/AN/AN/AN/AN/AUPXIUpexiN/AN/AN/AN/AN/AVIRIVirios TherapeuticsN/AN/AN/AN/AN/AZYBTZhengye BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioRAPPRapport TherapeuticsN/A45.9145.91UPXIUpexi0.350.580.53VIRIVirios TherapeuticsN/A7.277.27ZYBTZhengye BiotechnologyN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipRAPPRapport TherapeuticsN/AUPXIUpexi5.68%VIRIVirios Therapeutics9.05%ZYBTZhengye BiotechnologyN/AInsider OwnershipCompanyInsider OwnershipRAPPRapport TherapeuticsN/AUPXIUpexi31.60%VIRIVirios Therapeutics12.20%ZYBTZhengye BiotechnologyN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableRAPPRapport TherapeuticsN/A36.50 millionN/AN/AUPXIUpexi13037.92 million863,000OptionableVIRIVirios Therapeutics519.26 million16.91 millionOptionableZYBTZhengye Biotechnology27847.17 millionN/AN/AVIRI, ZYBT, UPXI, and RAPP HeadlinesRecent News About These CompaniesZYBT Zhengye Biotechnology Holding LimitedMay 30, 2025 | seekingalpha.comZhengye Biotechnology faces NASDAQ compliance issueMay 24, 2025 | investing.comZhengye Biotechnology Holding Limited Receives NASDAQ Delinquency Letter for Non-Compliance with Listing RequirementsMay 23, 2025 | quiverquant.comZhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-FMay 23, 2025 | globenewswire.comZhengye Biotechnology (NASDAQ:ZYBT) Trading Up 13.5% - What's Next?May 14, 2025 | marketbeat.comZhengye Biotechnology (NASDAQ:ZYBT) Stock Price Down 7.2% - Here's What HappenedMay 7, 2025 | marketbeat.comShould We Be Cautious About Zhengye Biotechnology Holding Limited's (NASDAQ:ZYBT) ROE Of 6.9%?April 7, 2025 | finance.yahoo.comZhengye Biotechnology Holding Ltd.April 3, 2025 | wsj.comZhengye Biotechnology Holding Limited (ZYBT)March 27, 2025 | finance.yahoo.comZhengye Biotechnology Holding Limited Announces Full Exercise of Underwriters' Over-Allotment OptionJanuary 14, 2025 | globenewswire.comZhengye Biotechnology Holding Limited Announces Closing of Initial Public OfferingJanuary 8, 2025 | globenewswire.comZhengye Biotechnology Holding Limited Announces Pricing of Initial Public OfferingJanuary 6, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVIRI, ZYBT, UPXI, and RAPP Company DescriptionsRapport Therapeutics NASDAQ:RAPP$10.23 +0.83 (+8.83%) As of 11:06 AM EasternRapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.Upexi NASDAQ:UPXI$10.91 -0.47 (-4.13%) As of 11:10 AM EasternUpexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida.Virios Therapeutics NASDAQ:VIRI$5.18 -0.11 (-2.08%) As of 05/30/2025Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.Zhengye Biotechnology NASDAQ:ZYBT$7.99 -1.17 (-12.77%) As of 11:09 AM EasternZhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Steel Dynamics Shares Climb After Tariff Announcement Why Super Micro Computer's Upside Could Trigger a Short Squeeze Zscaler Will Hit $360 Soon: Here’s the How and Why Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Ulta’s Beautiful Q1 Earnings Report Points to More Gains Ahead Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Chewy Stock Gets a New $7.1 Billion Investor and Analyst Upgrade Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
